Dendreon Rebounds In Q4 2011, But Can It Keep It Up In 2012?
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech reported gross product revenue for Provenge of approximately $82 million in Q4 2011, better than doubling Q4 2010 sales. Management credits improved reimbursement dynamics and sales execution.